Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex Pharmaceuticals : to Announce Third-Quarter 2021 Financial Results on November 2

10/22/2021 | 08:01am EST

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

(VRTX-WEB)


ę Business Wire 2021
All news about VERTEX PHARMACEUTICALS
12/08Wells Fargo Reinstates Vertex Pharmaceuticals With Overweight Rating, $270 Price Target
MT
12/03PUMP / DUMP #13 : This week's gainers and losers
12/02RBC Lifts Price Target on Vertex Pharmaceuticals to $265 From $250, Citing 'Strong' Pro..
MT
12/01Equities Led Higher Midday by Energy, Financials Following BioNTech CEO Comment on Vacc..
MT
12/01MIDDAY REPORT : US Stocks Led Higher by Energy, Financials Following BionTech CEO Comment ..
MT
12/01Vertex Pharmaceuticals Up Over 7%, Best Performer in The S&P 500 and Nasdaq 100 So Far ..
DJ
12/01Vertex's Kidney Disorder Drug VX-147 Reduces Proteinuria in Phase 2 Study
MT
12/01Vertex Pharmaceuticals to Advance VX-147 Kidney Drug After Phase 2 Study
DJ
12/01Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal ..
BU
12/01Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX..
CI
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 7 504 M - -
Net income 2021 2 296 M - -
Net cash 2021 8 318 M - -
P/E ratio 2021 23,4x
Yield 2021 -
Capitalization 52 531 M 52 531 M -
EV / Sales 2021 5,89x
EV / Sales 2022 4,93x
Nbr of Employees 3 400
Free-Float 99,8%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 206,61 $
Average target price 258,67 $
Spread / Average Target 25,2%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS-12.58%52 531
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
BEIGENE, LTD.21.92%32 376